168 related articles for article (PubMed ID: 32341034)
1. Theranostic Targeting of CUB Domain Containing Protein 1 (CDCP1) in Pancreatic Cancer.
Moroz A; Wang YH; Sharib JM; Wei J; Zhao N; Huang Y; Chen Z; Martinko AJ; Zhuo J; Lim SA; Zhang LH; Seo Y; Carlin S; Leung KK; Collisson EA; Kirkwood KS; Wells JA; Evans MJ
Clin Cancer Res; 2020 Jul; 26(14):3608-3615. PubMed ID: 32341034
[TBL] [Abstract][Full Text] [Related]
2. Theranostic Targeting of CUB Domain-Containing Protein 1 (CDCP1) in Multiple Subtypes of Bladder Cancer.
Chopra S; Trepka K; Sakhamuri S; Carretero-González A; Zhu J; Egusa E; Zhou J; Leung K; Zhao N; Hooshdaran N; Feng FY; Wells JA; Chou J; Evans MJ
Clin Cancer Res; 2023 Apr; 29(7):1232-1242. PubMed ID: 36648492
[TBL] [Abstract][Full Text] [Related]
3. CUB Domain-Containing Protein 1 (CDCP1) Is a Target for Radioligand Therapy in Castration-Resistant Prostate Cancer, including PSMA Null Disease.
Zhao N; Chopra S; Trepka K; Wang YH; Sakhamuri S; Hooshdaran N; Kim H; Zhou J; Lim SA; Leung KK; Egusa EA; Zhu J; Zhang L; Foye A; Sriram R; Chan E; Seo Y; Feng FY; Small EJ; Chou J; Wells JA; Aggarwal R; Evans MJ
Clin Cancer Res; 2022 Jul; 28(14):3066-3075. PubMed ID: 35604681
[TBL] [Abstract][Full Text] [Related]
4. Theranostic Targeting of CUB Domain Containing Protein 1 (CDCP1) in Pancreatic Cancer-Letter.
Birnbaum DJ; Finetti P; Birnbaum D; Bertucci F
Clin Cancer Res; 2020 Oct; 26(20):5539. PubMed ID: 33060289
[No Abstract] [Full Text] [Related]
5. Effective targeting of intact and proteolysed CDCP1 for imaging and treatment of pancreatic ductal adenocarcinoma.
Kryza T; Khan T; Puttick S; Li C; Sokolowski KA; Tse BW; Cuda T; Lyons N; Gough M; Yin J; Parkin A; Deryugina EI; Quigley JP; Law RHP; Whisstock JC; Riddell AD; Barbour AP; Wyld DK; Thomas PA; Rose S; Snell CE; Pajic M; He Y; Hooper JD
Theranostics; 2020; 10(9):4116-4133. PubMed ID: 32226543
[No Abstract] [Full Text] [Related]
6. CUB Domain-Containing Protein 1 (CDCP1) is a rational target for the development of imaging tracers and antibody-drug conjugates for cancer detection and therapy.
Khan T; Lyons NJ; Gough M; Kwah KKX; Cuda TJ; Snell CE; Tse BW; Sokolowski KA; Pearce LA; Adams TE; Rose SE; Puttick S; Pajic M; Adams MN; He Y; Hooper JD; Kryza T
Theranostics; 2022; 12(16):6915-6930. PubMed ID: 36276654
[No Abstract] [Full Text] [Related]
7. Targeting a proteolytic neoepitope on CUB domain containing protein 1 (CDCP1) for RAS-driven cancers.
Lim SA; Zhou J; Martinko AJ; Wang YH; Filippova EV; Steri V; Wang D; Remesh SG; Liu J; Hann B; Kossiakoff AA; Evans MJ; Leung KK; Wells JA
J Clin Invest; 2022 Feb; 132(4):. PubMed ID: 35166238
[TBL] [Abstract][Full Text] [Related]
8. Cleaved CDCP1 marks the spot: a neoepitope for RAS-driven cancers.
Donahue KL; Pasca di Magliano M
J Clin Invest; 2022 Feb; 132(4):. PubMed ID: 35166242
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of tumor metastasis: functional immune modulation of the CUB domain containing protein 1.
Fukuchi K; Steiniger SC; Deryugina E; Liu Y; Lowery CA; Gloeckner C; Zhou B; Kaufmann GF; Quigley JP; Janda KD
Mol Pharm; 2010 Feb; 7(1):245-53. PubMed ID: 19916495
[TBL] [Abstract][Full Text] [Related]
10. CUB domain-containing protein 1, a prognostic factor for human pancreatic cancers, promotes cell migration and extracellular matrix degradation.
Miyazawa Y; Uekita T; Hiraoka N; Fujii S; Kosuge T; Kanai Y; Nojima Y; Sakai R
Cancer Res; 2010 Jun; 70(12):5136-46. PubMed ID: 20501830
[TBL] [Abstract][Full Text] [Related]
11. Preclinical Molecular PET-CT Imaging Targeting CDCP1 in Colorectal Cancer.
Cuda TJ; He Y; Kryza T; Khan T; Tse BW; Sokolowski KA; Liu C; Lyons N; Gough M; Snell CE; Wyld DK; Rose S; Riddell AD; Stevenson ARL; Thomas PA; Clark DA; Puttick S; Hooper JD
Contrast Media Mol Imaging; 2021; 2021():3153278. PubMed ID: 34621145
[TBL] [Abstract][Full Text] [Related]
12. Antibody mediated CDCP1 degradation as mode of action for cancer targeted therapy.
Kollmorgen G; Niederfellner G; Lifke A; Spohn GJ; Rieder N; Harring SV; Bauss F; Burtscher H; Lammers R; Bossenmaier B
Mol Oncol; 2013 Dec; 7(6):1142-51. PubMed ID: 24055141
[TBL] [Abstract][Full Text] [Related]
13. Anti-CDCP1 immuno-conjugates for detection and inhibition of ovarian cancer.
Harrington BS; He Y; Khan T; Puttick S; Conroy PJ; Kryza T; Cuda T; Sokolowski KA; Tse BW; Robbins KK; Arachchige BJ; Stehbens SJ; Pollock PM; Reed S; Weroha SJ; Haluska P; Salomon C; Lourie R; Perrin LC; Law RHP; Whisstock JC; Hooper JD
Theranostics; 2020; 10(5):2095-2114. PubMed ID: 32104500
[TBL] [Abstract][Full Text] [Related]
14. CUB-domain containing protein 1 represses the epithelial phenotype of pancreatic cancer cells.
Miura S; Hamada S; Masamune A; Satoh K; Shimosegawa T
Exp Cell Res; 2014 Feb; 321(2):209-18. PubMed ID: 24384474
[TBL] [Abstract][Full Text] [Related]
15. Cell line and patient-derived xenograft models reveal elevated CDCP1 as a target in high-grade serous ovarian cancer.
Harrington BS; He Y; Davies CM; Wallace SJ; Adams MN; Beaven EA; Roche DK; Kennedy C; Chetty NP; Crandon AJ; Flatley C; Oliveira NB; Shannon CM; deFazio A; Tinker AV; Gilks CB; Gabrielli B; Brennan DJ; Coward JI; Armes JE; Perrin LC; Hooper JD
Br J Cancer; 2016 Feb; 114(4):417-26. PubMed ID: 26882065
[TBL] [Abstract][Full Text] [Related]
16. Photoimmunotherapy targeting biliary-pancreatic cancer with humanized anti-TROP2 antibody.
Nishimura T; Mitsunaga M; Sawada R; Saruta M; Kobayashi H; Matsumoto N; Kanke T; Yanai H; Nakamura K
Cancer Med; 2019 Dec; 8(18):7781-7792. PubMed ID: 31674732
[TBL] [Abstract][Full Text] [Related]
17. Preclinical Evaluation of a Fluorescent Probe Targeting Receptor CDCP1 for Identification of Ovarian Cancer.
He Y; Khan T; Kryza T; Jones ML; Goh JB; Lyons NJ; Pearce LA; Lee MD; Gough M; Rogers R; Davies CM; Gilks CB; Hodgkinson T; Lourie R; Barry SC; Perrin LC; Williams CC; Puttick S; Adams TE; Munro TP; Hooper JD; Chetty N
Mol Pharm; 2021 Sep; 18(9):3464-3474. PubMed ID: 34448393
[TBL] [Abstract][Full Text] [Related]
18. CUB Domain-containing Protein 1 (CDCP1) Is Down-regulated by Active Hexose-correlated Compound in Human Pancreatic Cancer Cells.
Kuhara K; Tokuda K; Kitagawa T; Baron B; Tokunaga M; Harada K; Terasaki M; Uehara O; Ohta T; Takai R; Hamada JI; Kobayashi M; Shimo T; Nagayasu H; Kuramitsu Y
Anticancer Res; 2018 Nov; 38(11):6107-6111. PubMed ID: 30396925
[TBL] [Abstract][Full Text] [Related]
19. Identification of CDCP1 as a hypoxia-inducible factor 2α (HIF-2α) target gene that is associated with survival in clear cell renal cell carcinoma patients.
Emerling BM; Benes CH; Poulogiannis G; Bell EL; Courtney K; Liu H; Choo-Wing R; Bellinger G; Tsukazawa KS; Brown V; Signoretti S; Soltoff SP; Cantley LC
Proc Natl Acad Sci U S A; 2013 Feb; 110(9):3483-8. PubMed ID: 23378636
[TBL] [Abstract][Full Text] [Related]
20. The CDCP1 Signaling Hub: A Target for Cancer Detection and Therapeutic Intervention.
Khan T; Kryza T; Lyons NJ; He Y; Hooper JD
Cancer Res; 2021 May; 81(9):2259-2269. PubMed ID: 33509939
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
